The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat After Response to First-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer
Abstract
PURPOSE: Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC). This trial was undertaken to determine whether adjuvant treatment with the metalloproteinase inhibitor marimastat could prolong survival in responding patients with SCLC after chemotherapy. PATIENTS AND METHODS: SCLC patients in complete or partial remission were eligible. They were stratified by radiotherapy (early, late, or none), stage (extensive or limited), response (complete or partial), and cooperative group (National Cancer Institute of Canada-Clinical Trials Group or European Organization for Research and Treatment of Cancer). They were randomized to receive marimastat 10 mg or placebo orally bid for up to 2 years. RESULTS: There were 532 eligible patients (266 marimastat and 266 placebo). Stage was limited for 279 patients (52%) and extensive for 253 (48%). Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection. The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P = .81). Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P = .90) Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat). Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity. Patients on marimastat had significantly poorer quality of life at 3 and 6 months. CONCLUSION: Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Metastatic potential correlates with enzymatic degradation of basement membrane collagen
Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., & Shafie, S. (1980) · Nature · doi:10.1038/284067a0 · Cited by 1,768
Changing views of the role of matrix metalloproteinases in metastasis
Chambers, A. F., & Matrisian, L. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.17.1260 · Cited by 1,588
The matrix‐degrading metalloproteinases
Matrisian, L. M. (1992) · BioEssays · doi:10.1002/bies.950140705 · Cited by 1,364
A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer
Pignon, J.-P., Arriagada, R., Ihde, D. C., Johnson, D. H., Perry, M. C., Souhami, R. L., Brodin, O., Joss, R. A., Kies, M. S., Lebeau, B., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212033272302 · Cited by 1,331
Bramhall, S. R., Rosemurgy, A., Brown, P. D., Bowry, C., Buckels, J. A. C., & for the Marimastat Pancreatic Cancer Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3447 · Cited by 438
Tokuraku, M., Sato, H., Murakami, S., Okada, Y., Watanabe, Y., & Seiki, M. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640513 · Cited by 261
Matrix metalloproteinase inhibition: A review of anti-tumour activity
Brown, P. D., & Giavazzi, R. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059091 · Cited by 224
Salo, T., Liotta, L. A., Keski‐Oja, J., Turpeenniemi‐Hujanen, T., & Tryggvason, K. (1982) · International Journal of Cancer · doi:10.1002/ijc.2910300520 · Cited by 195
Cited by
van Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
Role of matrix metalloproteinases (MMPs) in colorectal cancer
Zucker, S., & Vacirca, J. (2004) · Cancer and Metastasis Reviews · doi:10.1023/a:1025867130437 · Cited by 506
Jackman, D. M., & Johnson, B. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67569-1 · Cited by 503
Sher, T., Dy, G. K., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.3.355 · Cited by 498
Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
Vancheri, C., Failla, M., Crimi, N., & Raghu, G. (2010) · European Respiratory Journal · doi:10.1183/09031936.00077309 · Cited by 464
Metadata
- Authors
- Shepherd, F. A., Giaccone, G., Seymour, L., Debruyne, C., Bezjak, A., Hirsh, V., Smylie, M., Rubin, S., Martins, H., Lamont, A., Krzakowski, M., Sadura, A., & Zee, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-11-15
- Volume
- 20
- Issue
- 22
- Pages
- 4434-4439
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165132221
- Cited by
- 262
- References
- 16
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat After Response to First-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. https://app.cochat.ai/papers/10.1200/jco.2002.02.108
- The paper
- Shepherd, F. A., Giaccone, G., Seymour, L., Debruyne, C., Bezjak, A., Hirsh, V., Smylie, M., Rubin, S., Martins, H., Lamont, A., Krzakowski, M., Sadura, A., & Zee, B. (2002). Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat After Response to First-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2002.02.108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.